AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04382313 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: the adequate hydration group guided by Vigileo
Description: If the patient is mechanically ventilated, the following scheme is adopted: if SVV≤10%, then adjust the rehydration speed to 1 ml/kg/h; if 10%\<SVV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if SVV≥15%, then adjust the rehydration speed to 3 ml/kg/h. The hydration lasts 24 hours after operation, and the rehydration speed is changed according to the SVV. If the patient does not use mechanical ventilation, the following scheme is adopted: 250ml normal saline is administered within 10 minutes after direct PCI, and the rehydration volume changes to 125ml in patients with mild-to-moderate congestive heart failure. If the increment of SV≥15%, then adjust the rehydration speed to 3 ml/kg/h; if 10%≤the increment of SV\<15%, then adjust the rehydration speed to 2 ml/kg/h; if the increment of SV\<10%, then adjust the rehydration speed to 1 ml/kg/h. Reassessed every 1 hour until SV is stable，and the hydration also lasts 24 hours after operation.
Study NCT02325466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg
Study NCT02325466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: Aspirin 81mg
Study NCT02325466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: ticagrelor 90 mg
Study NCT02821481 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscular endurance exercise
Study NCT02821481 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Muscular endurance exercise
Study NCT01506479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Exercise
Description: Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
Study NCT01506479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vigorous Exercise
Description: Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
Study NCT01506479 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No Intervention
Description: No-exercise control (i.e., usual care);
Study NCT02651298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractional Co2-laser
Description: laser treatment
Study NCT02637505 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Arthroscopic debridement (AD)
Description: Arthroscopy With debridement procedure
Study NCT04544098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTATATE
Description: The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed for each patient: patients will receive two intra-arterial cycles of 7.4 GBq, unless toxicity occurs requiring dose modifications.
Study NCT03231865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive measurement of ZincProtoporphyrin IX
Description: Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
Study NCT00450450 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: Patients undergo allogeneic BMT
Study NCT00450450 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: allogeneic bone marrow transplantation
Description: Patients undergo allogeneic BMT
Study NCT00450450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00450450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00450450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV
Study NCT01148758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5323441
Description: cohorts receiving multiple doses iv
Study NCT03886376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Massage
Description: The deep massage group received 12 minutes of massage on the legs, arms and the back with three different sliding pressures.
Study NCT03886376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Superficial Massage
Description: The superficial massage group received 12 minutes of only one sliding pressure performed on the legs, arms and the back.
Study NCT03386240 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vicryl-plus, monocryl-plus, PDS-plus (Triclosan-coated Sutures)
Description: The intervention consists of using Plus group (Triclosan-coated Sutures)
Study NCT03386240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vicryl, monocryl, PDS (not coated with triclosan)
Description: Consists of equivalent sutures (not coated with triclosan) during cesarean delivery.
Study NCT04075058 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Hypofractionated Radiation therapy
Study NCT04075058 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiation therapy
Study NCT01716351 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients
Description: A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
Study NCT02865187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 600IU/day
Study NCT02865187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D 600IU/day
Study NCT02865187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Description: Hormonal contraceptives
Study NCT01412346 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Effects of a Nordic diet rich in plant-based foods and fish
Description: The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
Study NCT01412346 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Effects of a Nordic diet rich in plant-based foods and fish
Description: The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
Study NCT02978547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride 500Mg Tablet
Description: In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
Study NCT01495130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound imaging
Description: Undergo transrectal ultrasound
Study NCT01495130 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo robotic-assisted laparoscopic prostatectomy
Study NCT01430156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heme arginate (Normosang)
Description: 3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
Study NCT03515226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ITS based training
Description: Training using computerized adaptive training in addition to role play
Study NCT03515226 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Training
Description: Training using didactics and role plays
Study NCT02576535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractionated stereotactic radiosurgery
Study NCT02576535 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leskell gamma unit
Description: FDA approved device
Study NCT03490422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulpotomy
Description: Pulpotomy in mature carious permanent teeth
Study NCT01430156 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
Study NCT00970333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-FEPPA
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) of \[18F\]-FEPPA followed by serial PET imaging
Study NCT01313936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaiodobenzylguanidine (MIBG)
Description: Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
Study NCT03741179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA-withdrawn group
Description: Patients whith sFlt/PlGF ratio \< 38 at 24+0-27+6 weeks will be randomized into two arms of the trial. Patients allocated in the experimental arm will stop the ASA treatment.
Study NCT03622307 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD Therapy Combined with VT Ablation
Description: S-ICD implantation and VT ablation/substrate modification among patients with a secondary prevention indication for an ICD
Study NCT04417920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Express implant device
Description: Operative technique in group I (Express implant) was as in group II (trabeculectomy) except with no sclerectomy or peripheral iridectomy , the steps included conjunctival peritomy superior-temporally away from the site of the fibrotic bleb at 12 o'clock, placed on the episclera under the conjunctiva and Tenon's capsule for a contact time of 3 minutes, ,triangular scleral flap , scleral dissection forward to the clear cornea to allow exposure of scleral spur then creation of a pilot hole is fashioned using a sapphire blade (Alcon laboratories,USA) then Express shunt 3 mm long device and external diameter 400 microns was implanted followed by closure of scleral flap and conjunctiva.~While in group II, Trabeculectomy with Mitomycin-C was done in superior-temporal region away from the fibrotic bleb at 12 o, clock.
Study NCT01095016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meptin swinghaler
Description: * Dose: 10ug/puff, 2 puffs daily~* Frequency: QD (total 20ug/day)~* Treatment duration: 2 days
Study NCT01095016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Berotec
Description: * Dose: 100ug/puff, 2 puffs daily~* Frequency: QD (total 200ug/day)~* Treatment duration: 2 days
Study NCT02601131 — intervention group
Intervention type: BIOLOGICAL
Intervention: Platelet transfusion
Study NCT02622542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BMT+TEVAR
Description: These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
Study NCT02622542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BMT
Description: Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
Study NCT04326907 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous centrifuged adipose tissue (CAT) injection after anal fistulectomy
Description: Collection and injection of autologous adipose tissue in complex anal fistulas in one surgical step under locoregional or general anesthesia.
Study NCT01808287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3 Transcatheter Heart Valve
Description: The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
Study NCT02424747 — intervention group
Intervention type: OTHER
Intervention: Acute Kidney Injury
Description: We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission.
Study NCT03966001 — intervention group
Intervention type: OTHER
Intervention: Transvaginal sonography at six months after cesarean section
Description: In the sixth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
Study NCT03966001 — intervention group
Intervention type: OTHER
Intervention: Transvaginal sonography at twelve months after cesarean section
Description: In the twelfth month after cesarean section, Women in both groups will undergo a detailed pelvic examination and transvaginal ultrasonographic evaluation for the cesarean scar defect.
Study NCT01509430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training
Description: 12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
Study NCT01509430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Exercise Training
Description: 12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
Study NCT00798239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
Description: 150 micorgrams/cc BVF
Study NCT00798239 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Iliac crest autograft
Description: autograft
Study NCT00798239 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules
Description: 750 micrograms/cc BVF
Study NCT04509674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Empagliflozin
Study NCT04509674 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04007237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: shampoo with different composition
Description: To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
Study NCT04007237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: shampoo with different composition
Description: To reveal the mycological efficacy, safety, recurrence and cost-effectiveness of selenium sulfide 1.8% shampoo (SeS2) and ketoconazole 2% shampoo in the treatment of pityriasis versicolor.
Study NCT04108845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15-Valent Pneumococcal Conjugate Vaccine
Description: 3/1 dose(s) according to age of subjects. Single intramuscular dose contains 0.5ml 15-Valent Pneumococcal Conjugate Vaccine.
Study NCT01076062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction of Labor
Description: If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
Study NCT00539383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG1005
Description: IV infusion once every 21 days
Study NCT01839591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter ALAIR
Description: Catheter ALAIR Radiofrequency 65°
Study NCT03517930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT03517930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT02325466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Placebo
Study NCT02325466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor Placebo
Study NCT03517930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT03517930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT03555981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Kangaroo Mother Care
Description: Continuous skin-to-skin contact between baby and mother/caregiver started within 24h of hospital admission
Study NCT03555981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Incubator or radiant heater care until stable, off oxygen and >24h of admission, at which point will start intermittent or continuous kangaroo mother care
Study NCT04262505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Group
Description: Participants will be advised to follow a traditional Mediterranean diet
Study NCT04262505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Group
Description: Participants will be advised to follow the Healthy Eating Guidelines in Ireland
Study NCT02059460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
Study NCT02059460 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01930747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: measure effect on laparoscopic workspace
Study NCT01930747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1 MAC sevoflurane inhalation is given
Study NCT01930747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanyl
Description: remifentanyl is given in infusion
Study NCT03973840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: dose was given orally and allowed to reach steady state
Study NCT01912651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalexin
Description: This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
Study NCT02875860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoldBal2 detachable balloon
Description: Placement of the balloon using the plug/unplug method.
Study NCT02875860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baltaccidbpe100 Delivery Catheter
Description: The catheter assists with implanting the balloon in the plug/unplug method.
Study NCT02875860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized postnatal care
Description: After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
Study NCT02875860 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized postnatal care
Description: After birth, the babies will receive standardized postnatal care at a tertiary center used to manage babies with CDH. The recommendation is that they adhere to consensus guidelines published on the study website. For detailed description on this please visit https://www.karger.com/Article/Abstract/320622
Study NCT01835067 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
Study NCT01835067 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ranibizumab
Description: Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls